Pretreatment ctDNA concentration (conc.) reflects clinical disease features and is associated with outcome. (A) Waterfall plot of pretreatment ctDNA conc. in study patients measured in log hGE/mL. Bars are colored according to patient’s best response to treatment. (B) Box and dot plot of pretreatment ctDNA conc. (y-axis) according to MIPI score. P value indicates significance of Kruskal-Wallis test. (C-D) Scatterplots with linear regression lines according to pretreatment ctDNA conc. and LDH level of upper reference value (C) and PB MCL involvement by FC (D). Spearman correlation coefficients and P values shown. (E) Box and dot plot of pretreatment ctDNA conc. according to TP53 mutation status. Mann-Whitney U test. (F) Kaplan-Meier survival estimate for OS according to pretreatment ctDNA conc. categorized to high and low groups. (G) Forest plot of Cox regression proportional hazards model with HRs, 95% CIs, and P values for pretreatment ctDNA conc as a continuous variable (log hGE/mL) for OS and PFS. (H) Forest plots of Cox regression proportional hazards multivariable models for OS with pretreatment ctDNA conc as a continuous variable with TP53 mutation status and number of previous therapies received. CI, confidence interval; LDH, lactate dehydrogenase; NA, not available; ND, not detected; PD, progressive disease; PR, partial response.